Product Description

Vinblastine is a vinca alkaloid chemotherapeutic agent that binds to tubulin and inhibits microtubule polymerization, thereby preventing mitotic spindle formation and arresting cells in metaphase, ultimately leading to apoptosis in rapidly dividing cancer cells. It is commonly used in the treatment of Hodgkin and non‑Hodgkin lymphomas, testicular cancer, breast cancer, and other malignancies. However, the development of drug resistance remains a major challenge limiting its long‑term efficacy.

Mechanistically, vinblastine resistance arises through multiple cellular adaptations. Alterations in β‑tubulin isotypes (particularly class III β‑tubulin) or mutations in tubulin‑binding sites reduce drug affinity, while upregulation of efflux transporters such as P‑glycoprotein (MDR1/ABCB1) decreases intracellular drug accumulation. Additionally, activation of survival pathways—including PI3K/Akt, MAPK, and NF‑κB signaling—promotes anti‑apoptotic responses. Changes in microtubule‑associated proteins (MAPs) and enhanced autophagy or epithelial–mesenchymal transition (EMT) also contribute to reduced drug sensitivity.

Understanding these mechanisms is critical for designing strategies to overcome resistance, such as combination therapy with efflux transporter inhibitors, targeting compensatory survival networks, or employing patient‑derived resistant cell models to guide personalized therapy development.

Data

Target Background

Vinblastine is a vinca alkaloid chemotherapeutic agent that binds to tubulin and inhibits microtubule polymerization, leading to disruption of mitotic spindle formation, cell cycle arrest at metaphase, and apoptosis in rapidly dividing cancer cells. It is widely used in the treatment of Hodgkin and non‑Hodgkin lymphomas, testicular cancer, breast cancer, and other malignancies. However, the development of drug resistance remains a major challenge limiting its long‑term efficacy.

Mechanistically, vinblastine resistance arises through multiple cellular adaptations. Alterations in β‑tubulin isotypes (particularly class III β‑tubulin) or mutations in tubulin‑binding sites reduce drug binding affinity, while upregulation of efflux transporters such as P‑glycoprotein (MDR1/ABCB1) decreases intracellular drug accumulation. Additionally, activation of survival pathways—including PI3K/Akt, MAPK, and NF‑κB signaling—promotes anti‑apoptotic responses. Changes in microtubule‑associated proteins (MAPs) and enhanced autophagy or epithelial–mesenchymal transition (EMT) also contribute to reduced drug sensitivity.

Understanding these mechanisms is critical for designing strategies to overcome resistance, such as combination therapy with efflux inhibitors, targeting compensatory signaling networks, or employing patient‑derived resistant cell models to guide personalized therapy development.